BTIG Reiterates Buy Rating on MNPR with $117 Target
BTIG maintains its positive outlook on MNPR, setting a $117 price target, a 23.73% upside from the current price.
Key Points
- BTIG reiterated its Buy rating on MNPR with a $117 price target on June 30, 2026.
- BTIG's $117 price target implies 23.73% upside from Monopar Therapeutics Inc.'s ($MNPR) current $94.56 share price.
- Shares of MNPR traded near $94.56 on Tuesday, with insider buying reported earlier this year.
- Other analysts, like HC Wainwright & Co., also reiterated Buy ratings with targets of $105.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG reiterated its Buy rating for MNPR on June 30, 2026, setting a price target of $117. Analyst Jeet Mukherjee maintains a positive outlook on the stock, which traded near $94.56 on Tuesday.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in MNPR
Janus Henderson Group PLC held steady with 1,317,410 shares valued at about $72.1 million. RA Capital Management, L.P. also kept its position unchanged, holding 667,207 shares worth around $36.6 million. Meanwhile, Saturn V Capital Management LP increased its stake by 19,925 shares to a total of 345,626 shares, valued at approximately $18.9 million, marking a 6.1% increase. Deerfield Management Company, L.P. significantly boosted its holdings by 153,187 shares, a hefty 89.8% increase, bringing its total to 323,745 shares worth $17.7 million. In contrast, Adage Capital Partners GP, L.L.C. reduced its holdings by 330,272 shares, a 51.6% decrease, ending with 309,195 shares valued at $16.9 million.
Monopar Therapeutics Inc. Stock Down 15.5%
Shares of MNPR traded near $94.56 on Tuesday. The stock has seen varied institutional activity, with some funds increasing their stakes and others reducing them. This movement reflects differing views on MNPR's future potential.
$MNPR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Monopar Therapeutics Inc.
Recent insider activity at MNPR includes several purchases. On March 2, 2026, Susan Rodriguez, the Chief Customer Service Officer, bought 48,728 shares. Earlier, on January 28, 2025, Chandler Robinson, the CEO, acquired 62,815 shares. Additionally, Patrice Rioux purchased 2,000 shares on January 1, 2026, and Andrew Cittadine, the COO, bought 4,326 shares on December 31, 2025.
Analysts Set New Price Targets
On June 30, 2026, BTIG maintained its Buy rating on MNPR with a $117 price target. A day prior, HC Wainwright & Co. reiterated its Buy rating with a target of $105. Earlier in the year, Chardan Capital also maintained a Buy rating with a $100 target on March 30, 2026. These consistent Buy ratings suggest analysts see potential upside for MNPR.
Bottom Line
BTIG's reiterated Buy rating and $117 target for MNPR highlight continued confidence in the stock's prospects. Investors often track these analyst updates as part of their decision-making process. It's important to remember that these ratings reflect past analyses and may not indicate current positions or future performance.
Get Monopar Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $MNPR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.